Clinical Trial Update: Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

Phase I open-label dose-escalation trial of the investigational compound GSK1059615 in patients with solid tumors or lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• GSK1059615 (GSK1059615)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Solid Tumours | Phase 1 | Status: TERMINATED